Mannkind Corp

The Credit Agreement provides for an initial term loan of $75.0 million (“Initial Term Loan”), a delayed draw term loan (“DDTL”) of up to $125.0 million and an additional incremental delayed draw term loan commitment of $175.0 million solely to finance a portion of the fees, premiums, expenses and other transaction costs incurred in connection with the Acquisition (“Incremental Term Loan”).

SEC original ↗Mannkind Corp — Earnings release (8-K exhibit)EX-99Dec 15, 2025

The Initial Term Loan was drawn on August 6, 2025, and, on the Close Date, MannKind drew the full $175.0 million of the Incremental Term Loan and drew $75.0 million on the DDTL to finance the Acquisition.

SEC original ↗Mannkind Corp — Earnings release (8-K exhibit)EX-99Dec 15, 2025

Borrowings under the Credit Agreement bear interest at a rate of at a rate per annum equal to one, three or six month term SOFR (at MannKind’s election), subject to a 2% floor, plus a margin of 4.75%.

SEC original ↗Mannkind Corp — Earnings release (8-K exhibit)EX-99Dec 15, 2025

In accordance with the Merger Agreement, MannKind paid off and repurchased these amounts on the Closing Date.

SEC original ↗Mannkind Corp — Earnings release (8-K exhibit)EX-99Dec 15, 2025

The interest rate assumed for purposes of preparing this pro forma financial information was based off the term SOFR plus an applicable interest rate margin as of the Closing Date, and the impacts of the amortization of the debt issuance costs.

SEC original ↗Mannkind Corp — Earnings release (8-K exhibit)EX-99Dec 15, 2025

The Blackstone Credit Facility contains restrictive covenants that may materially limit our operating flexibility.

SEC original ↗Mannkind Corp — 10-K Annual report10-KFeb 26, 2026

We may not realize the anticipated benefits of the scPharma acquisition or any future acquisition or strategic transaction; we may be unable to successfully integrate new products, technologies or businesses we acquire.

SEC original ↗Mannkind Corp — 10-K Annual report10-KFeb 26, 2026

Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

SEC original ↗Mannkind Corp — 10-K Annual report10-KFeb 26, 2026

, our strategy has been to establish regional partnerships in foreign jurisdictions where there are commercial opportunities, subject to the receipt of necessary foreign regulatory approvals.

SEC original ↗Mannkind Corp — 10-K Annual report10-KFeb 26, 2026

In August 2025, we announced the expansion of our collaboration, pursuant to which we will formulate MNKD-1501, a second investigational molecule using our proprietary technologies, and United Therapeutics will conduct preclinical and clinical development activities.

SEC original ↗Mannkind Corp — 10-K Annual report10-KFeb 26, 2026

This program is focused on bumetanide, a more potent loop diuretic than furosemide.

SEC original ↗Mannkind Corp — 10-K Annual report10-KFeb 26, 2026

Legal Proceedings 48 Item 4.

SEC original ↗Mannkind Corp — 10-K Annual report10-KFeb 26, 2026

These statements are only predictions or conclusions based on current information and expectations and involve a number of risks and uncertainties.

SEC original ↗Mannkind Corp — 10-K Annual report10-KFeb 26, 2026

Manufacturing risks may adversely affect our ability to manufacture our products and Tyvaso DPI, which could reduce our gross margin and profitability.

SEC original ↗Mannkind Corp — 10-K Annual report10-KFeb 26, 2026

International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.

SEC original ↗Mannkind Corp — 10-K Annual report10-KFeb 26, 2026

If third-party payers do not cover our approved products, such products might not be prescribed, used or purchased, which would adversely affect our revenues.

SEC original ↗Mannkind Corp — 10-K Annual report10-KFeb 26, 2026

If our data or our information technology systems, or those of third parties with whom we work, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.

SEC original ↗Mannkind Corp — 10-K Annual report10-KFeb 26, 2026